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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. This study was conducted to investigate the effects of α lipoic
acid and coenzyme Q10 on plasma levels of lipids, asymmetric
dimethylarginine, oxidative stress in fructose fed rats which provide
a model of dietary induced insulin resistance and to evaluate
vascular changes developing in these rats by histologically. Male
Sprague Dawley rats were used in this study. The animals were
divided into 4 groups. Group 1 did not receive any medication and
served as a control. Group 2 received a regular diet and water ad
libitum and fructose was administered as % 10 solution in drink 
ing water. Group 3 received α lipoic acid (100 mg/kg/day) i.p. for
5 weeks and Group 4 received coenzyme Q10 (10 mg/kg/day) i.p.
for 5 weeks. For determination of plasma asymmetric dimethylar 
ginine, glutathione and malondialdehyde levels, high performance
liquid  chromatography system was used. Homeostatic model
assessment as a measure of insulin resistance was calculated. Lipid
profile measurements were determined using enzymatic assay on
an Auto analyzer. The high fructose diet was significantly associated
with an increase in levels of plasma LDL, VLDL and total cholesterol
and decrease in level of HDL cholesterol. Plasma asymmetric
dimethylarginine, malondialdehyde and glutathione levels were
also increase in these rats. α lipoic acid or coenzyme Q10 supple 
mentation was found to have some positive effect on these
parameters. These findings were also demonstrated by morpho 
logical observation of the aorta. We demonstrated that admin 
istration of α lipoic acid and coenzyme Q10 notably suppresses
oxidative and nitrative stress, hyperinsulinemia, insulin resistance
developing in fructose fed rats, a model of metabolic syndrome
(MS). These positive effects of α lipoic acid or coenzyme Q10 can
be attributed to its antioxidant activity.
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Introduction Metabolic syndrome (MS) characterized by hyperglycemia,
hyperlipidemia and hypertension is a significant risk factor
for cardiovascular disease.(1) Insulin resistance (IR) is a central
component of metabolic syndrome.(2) Fructose-fed rats (FFRs)
provide a model of dietary-induced insulin resistance to indicate
the pathophysiological mechanisms (metabolic and cardiovascular
changes) associated with MS.(3,4) The metabolic effect of a fructose
diet is associated with oxidative stress,(5) but the precise mecha-
nism is not fully understood. Reactive oxygen species (ROS) play
a physiological role in the vessel wall. Dietary factors play a key
role in the development or prevention of various human diseases,
including cardiovascular disease and MS.(6) Some studies suggest
a strong association between IR and endothelial dysfunction.(7)
Endothelium-derived nitric oxide (NO) is the most potent endo-
genous substance which is synthesized by the endothelial enzyme
NO synthase (e-NOS) from the amino acid L-arginine.(8) Experi-
mental and clinical data show that endogenous inhibitors of
e-NOS, such as asymmetric dimethylarginine (ADMA), may be
responsible for endothelial dysfunction in which ADMA plasma
levels have been found elevated.(9–14) Therefore, ADMA plasma
levels appear to be dynamically regulated and can be correlated
with measure of NO bioavailability. Endothelial dysfunction
induces a reduction in vascular relaxation, linked to a decrease in
the bioavailability of nitric oxide (NO)(15) and an increase in levels
of oxidative stress(16) following the overproduction of super oxide
anion (O2￿−). The role of oxidative stress in the development of IR
has been demonstrated by several studies.(17) Furthermore, systemic
oxidative stress is associated with insulin resistance.(18–20)
Coenzyme Q10 (CoQ10) is an electron carrier in the mito-
chondrial respiratory chain. In addition to its role in mitochondria,
CoQ10 acts as an antioxidant, scavenging free radicals and
inhibiting lipid peroxidation.(21,22) Recent studies have provided
beneficial effects of CoQ10 in various disorders related to oxida-
tive stress like hypertension and heart failure.(23–25) It has been
reported that CoQ10 concentrations and redox status are associated
with components of MS.(26)
α-lipoic acid (ALA), also known as 6,8-thioctic acid has
generated considerable clinical interest as a redox-modulating
agent.(27) Biologically, α-lipoic acid functions as a cofactor of
oxidative decarboxylation reactions in glucose metabolism to
provide energy.(28) It has been used in the western world for a long
time to treat complications associated with diabetes.(29) In addition
to its role in glucose metabolism, but may also acts as an anti-
oxidant in vitro and in vivo.(30) In vitro experiments have shown
that ALA is potent scavengers of reactive oxygen species which
quenches singlet oxygen, hydroxyl radical and hypochlorus
acid.(31)
Thus, it would be important to establish whether exogenous
administration of CoQ10 and ALA are effective for prophylaxis
and therapy of MS. This study aimed to investigate the effect of
exogenous CoQ10 and ALA administration in the fructose-fed
rat on the levels of lipids, ADMA, NO and glutathione. We also
investigated the possible protective effects of coenzyme Q10 and
ALA on the vascular changes developed in these rats by histo-
logically.
Materials and Methods
Animals and treatment. Male Sprague Dawley rats of body
weight ranging from 210 to 230 g were used in this study. They
were housed in an animal room under controlled conditions on a
12-h light/dark cycle and constant temperature (22°C). Food
and water were supplied ad libitum. All rats were fed a standard
rat chow before beginning the study and continued to consume
standard rat chow composed of 21% protein, 4% fat, 50% carbo-
hydrate (vegetable starch), and 4.5% cellulose for the entire study
duration. Both diets contained a standard mineral and vitamin
mixture. All protocols described were reviewed and approved by




The animals were divided into 4 groups and were maintained as
follows:
Group 1 (CON) (n = 7) – This group received regular diet and
water ad libitum. This group did not receive any medication and
served as a control. After 8 weeks, this group recieved serum
physiologic (SF) (0.5 mL/day) intraperitoneally (i.p.) for 5 weeks.
Group 2 (FRU) (n = 9) – This group received a regular diet and
water ad libitum and fructose was administered as % 10 solution in
drinking water. After 8 weeks, this group recieved SF (0.5 mL/day)
i.p. for 5 weeks.
The other groups of rats were given one of the following
treatments (Group 3 and 4).
Group 3 (FRU + ALA) (n = 9) – This group received a regular
diet and water ad libitum and fructose was administered as % 10
solution in drinking water. After 8 weeks, this group received
ALA (100 mg/kg/day) i.p. for 5 weeks.
Group 4 (FRU + CoQ10) (n = 9) – This group received a regular
diet and water ad libitum and fructose was administered as % 10
solution in drinking water. After 8 weeks, this group received
CoQ10 (10 mg/kg/day) i.p. for 5 weeks.
Body weights of animals were recorded at the baseline and
after the treatment. Blood samples from animals were collected
by decapitation and serum was separated by centrifugation and
samples were kept at −70°C until the measurements were performed.
Biochemical analysis. Serum samples were analyzed for
glucose, triglyceride (TG), HDL-cholesterol, LDL-cholesterol and
total cholesterol (TC). Glucose and lipid profile measurement
were determined using enzymatic assay on an Auto analyzer
(Olympus AU 600, Hamburg, Germany). Quantitative determina-
tion of serum insulin concentration was performed with rat/mouse
Enzyme-linked immunosorbent assay (ELISA) kit (Linco research).
Insulin levels were expressed as ng/mL in ELISA kit and they
were converted to mU/ml. Homeostatic model assessment
(HOMA) as a measure of insulin resistance was calculated by the
formula: insulin (mU/ml) × [glucose (mmol/l/22.5)].
For determination of plasma ADMA levels, HPLC system
was used. This method allows to analized the asymmetric
dimethylarginine (ADMA) with clean-up columns procedure and
derivatization. Besides this method allow to analyze the arginine
and symmetric dimethylarginine (SDMA). After derivatization,
50 μl of solution are injected in HPLC system and analized by
Fluorescence. The sensitivity of this method was <0.01 μmol/l and
linearity was >16,00 μmol/l.
Determinations of total and reduced glutathione (GSH) were
determined by HPLC. EDTA-blood was used in this test system.
For the determination of glutathione the sample is divided in two
aliquots. One is reduced and the total amount of glutathione is
measured. The other aliquot is treated without reduction solution,
which determines only the reduced glutathione. During the
derivatisation reaction glutathione is converted into a fluorescent
probe. The following precipitation step removes high molecular
substances. After centrifugation the fluorescent probe is cooled
(2–8°C) and injected into the HPLC system. The isocratic
separation via HPLC at 30°C using a reversed phase column in
two runs. One run lasts 4 min. The chromatograms are recorded
by a fluorescence detector. The quantification is performed with
the delivered EDTA-blood calibrator; the concentration is calcu-
lated by the internal standard method. The amount of oxidized
glutathione is calculated by substraction of: Glutathionetotal–
Glutathionereduced the difference was divided by two because oxi-
dized glutathione (GSSG) consists of two reduced GSH molecules.
Intra-Assay CV for GSHtotal is 1.2% (551 μmol/l) and for
GSHreduced is 1.2% (286 μmol/l). Inter-Assay CV for GSHtotal is
2.8% (554 μmol/l) and for GSHreduced is 3.5% (271 μmol/l).
Determination of plasma MDA level was also determined by
HPLC. For the determination of malondialdehyde a derivatisation
step, in which protein bound malondialdehyde is hydrolysed and
converted into a fluorescent probe (60 min at 95°C) is performed.
The fluorescent probe is then cooled (2–8°C), centrifuged, mixed
with a reaction solution and injected into the HPLC system. The
isocratic separation via HPLC at 30°C, using a ‘reversed phase’
column, lasts 4 min for one sample. The chromatograms are
recorded by a fluorescence detector. The quantification is per-
formed with the delivered calibrator; the concentration is calcu-
lated via integration of the peak heights. Intra-Assay CV: 6.4%
(2.55 μmol/l) Inter-Assay CV: 7.5% (2.50 μmol/l) [n = 6].
Plasma NO levels were measured in triplicate after conversion
of nitrate to nitrite by nitrate reductase, and nitrite was measured
by using the Griess reaction, as described previously.(32) The
results were expressed as μmol/ml.
Vascular histological analysis. Fixations of vessel samples
obtained from control and other groups were made in % 10
formaldehyde. After that, paraffin sections at 4 micron thickness
obtained from routine pathological processes were stained with
hematoxylin-eosin and examined by light microscopy.
Statistical analysis. The results are expressed as mean ± SD.
Analysis of the data was performed by one-way analysis of
variance (ANOVA) and subsequent analysis was performed using
the Tukey test. The p values smaller than 0.05 were selected to
indicate statistical significance between groups.
Results
Body weight, glucose, HOMA IR and lipid profile.
Fructose fed rats had a significant increase in body weight.
Fructose fed rats had a higher body weight compared with controls
(p<0.0001). ALA and CoQ10 treatment given to fructose fed rats
for 8 weeks affect body weight gain during the experimental
period. Body weights were decreased during the treatment of
ALA and CoQ10 at the end of the experiment compared with only
fructose fed rats (p<0.05, p<0.01). Serum levels of LDL, TG and
total cholesterol were increased and HDL cholesterol was
decreased in fructose fed rats compared with control rats at the
end of the experiment (p<0.0001). The treatment of ALA and
coenzyme Q10 at the end of experiment improved the lipid
levels. Serum levels of LDL, TG and total cholesterol were
significantly decreased and HDL cholesterol was significantly
increased in group 3 and 4 compared with fructose fed rats
(p<0.0001). But there were no significant difference between
ALA treatment and Coenzyme Q10 treatment (Table 1).
In the end of the experiments, the highest levels of glucose and
HOMA-IR were observed in the fructose fed group compared
with control, group 3 and group 4 (p<0.0001,  p<0.05,  p<0.01
respectively). Administration of ALA and CoQ10 were improved
the glucose and HOMA-IR levels. Treatment with ALA and
CoQ10 were significantly decreased the glucose level compared
with fructose fed rats (p<0.0001), but as shown in lipid levels,
there were no significant difference in glucose levels between
ALA and CoQ10 treatment. HOMA-IR level was decreased in
ALA treatment group compared with fructose fed group
(p<0.001). Coenzyme Q10 administration more improved HOMA-
IR than ALA treatment, HOMA-IR was significantly decreased
in this group compared with fructose fed rats (p<0.0001).
Levels of ADMA, MDA, NO, total glutathione, reduced
glutathione and NO. The high fructose diet was significantly
associated with an increase in levels of plasma ADMA (0.95 ±
0.21 μmol/L vs 2.51 ± 1.19 μmol/L,  p<0.0001) leading to a
significant reduction in the L-arginine level (81.39 ± 6.92 μmol/l
vs 71.08 ± 8.35 μmol/l,  p<0.05). No significant difference was
seen in the levels of SDMA between control and fructose fed
rats. ALA and CoQ10 administration were decreased ADMA
levels compared with controls (p<0.01, p<0.001, respectively).
MDA and NO levels were lead similar effects as shown in ADMA
levels. These parameters were increased in high fructose diet
group compared with controls (p<0.0001) and treatment with
ALA or CoQ10 decreased the levels of MDA and NO levels J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 147
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(Table 2). In contrast, total and reduced glutathione levels were
decreased in high fructose diet group compared with controls
(p<0.0001) and treatment with ALA or CoQ10 increased the
levels of these parameters (Table 2).
To further investigate the relationships between biochemical
characteristics and HOMA-IR as continuous variables, the following
statistical correlations were identified: ADMA (r = 0.55, p = 0.001),
glutathionetotal (r = −0.46, p = 0.006), glutathionereduced (r = −0.60,
p = 0.0001), MDA (r = 0.49,  p = 0.003) and NO (r = 0.44,
p = 0.001) (Table 3).
Morphological observation of the aorta. When compared
with control group (Fig. 1), histopathological examination of
vessels of group 2 revealed that there were lymphocytic infiltration
in place, hypertrophy of smooth muscles and edema (Fig. 2–4);
in ALA-administered group, it was noted that perivascular
lymphocytic infiltration was significiantly decreased and even
disappeared completely in place (Fig. 5). In CoQ10-administered
group, appearances of vessels were almost same with control
group and poor lymphocytic infiltration was seen in perivascular
area (Fig. 6).
Discussion
In this study, we found that ALA or Coenzyme Q10 administra-
tion prevent the increase of ADMA, the development of insulin
resistance, oxidative stress, and vascular changes in an experi-
mental model of metabolic syndrome induced by fructose
administration. Insulin resistance has been implicated as a central
pathogenic feature of MS in human and animal models.(1) As
shown in previous studies reported by a group,(4,33,34) in our study,
FFRs developed insulin resistance and increased oxidative stress,
plasma ADMA level and histological vascular alterations. Chronic
administration of ALA and CoQ10 not only prevented the increase
in ADMA and oxidative stress but also reduced vascular peri-
vascular lymphocytic infiltration and edema in FFRs.
The fructose rich diet used in our experimental model(3) induced
the development of pathophysiological characteristics associated
with metabolic syndrome, including hyperglycemia and dys-
lipidemia.(35,36) Our results are in accordance with a recent study(37)
which indicated that fructose-fed Sprague–Dawley rats manifested
major characteristics of human metabolic syndrome. Fructose is a
simple carbohydrate, with interesting physico-chemical properties
such as its strong sweetening power and its hygroscopic nature.
The highest concentration of fructose found in natural foods is
about 42%, and it is the principal sugar added to processed
foods.(35) Unlike glucose, fructose does not directly stimulate
insulin secretion because pancreatic beta-cells have very low
levels of the fructose transporter GLUT5.(38) An additional
important observation in this study pertained to the weight loss
noted with ALA. α-lipoic acid has been described to have appetite
suppressant effect through an AMP kinase mechanism in the
Table 1. Changes in body weight and serum lipids
ap<0.0001, compared with control; bp<0.05, compared with group 3; cp<0.01, compared with group 4; dp<0.005, compared with control; ep<0.0001,
compared with group 2; fp<0.05, compared with control.
Group 1 (CONTROL) Group 2 (FRU) Group 3 (FRU + ALA) Group 4 (FRU + CoQ10)
n =7 n =9 n =9 n =9
Body weight (g) (Initial) 212.57 + 11.04 218.66 + 9.65 219.44 + 15.28 220.55 + 13.21
Body weight (g) (Final) 312.71 ± 6.15 362.11 ± 20.03a,b,c 345.22 ± 13.31a 342.11 ± 12.46a
Glucose (mg/dl) 98.57 ± 6.42 147.88 ± 8.97a 115.44 ± 6.98a,e 109.66 ± 4.58d,e
LDL C (mg/dl) 28.28 ± 3.19 59.88 ± 3.68a 38.55 ± 6.10a,e 34.22 ± 4.43f,e
VLDL C (mg/dl) 20.48 ± 1.37 33.97 ± 1.68a 25.26 ± 1.54a,e 24.82 ± 1.36a,e
Trigliserid (mg/dl) 102.42 ± 6.87 169.88 ± 8.44a 126.33 ± 7.71a,e 124.11 ± 6.80a,e
Total C (mg/dl) 82.57 ± 4.15 118.22 ± 3.89a 97.22 ± 8.52a,e 96.00 ± 6.63a,e
HDL C (mg/dl) 34.14 ± 2.79 25.11 ± 4.13a 35.77 ± 5.09e 37.11 ± 4.07e
Table 2. Effects of ALA and CoQ10 treatments on plasma variables in rats
ap<0.0001, compared with control; bp<0.01, compared with group 2; cp<0.001, compared with group 2; dp<0.05, compared with group 4; ep<0.005,
compared with group 2; fp<0.05, compared with control; gp<0.0001, compared with group 2; hp<0.01, compared with control; ip<0.001, compared
with control; jp<0.05, compared with group 2; kp<0.005, compared with group 2.
Group 1 (CONTROL) Group 2 (FRU) Group 3 (FRU + ALA) Group 4 (FRU + CoQ10)
n =7 n =9 n =9 n =9
ADMA (μmol/l) 0.95 ± 0.21 2.51 ± 1.19a 1.61 ± 0.27b 1.39 ± 0.30c
SADMA (μmol/l) 0.66 ± 0.14 0.87 ± 0.42 0.46 ± 0.09d,e 0.75 ± 0.24
ARJININ (μmol/l) 81.39 ± 6.92 71.08 ± 8.35f 74.54 ± 6.08 82.54 ± 11.56b
Insulin (ng/ml) 0.41 ± .14 0.93 ± 0.14a 0.68 ± 0.11a,g 0.67 ± 0.12a,g
HOMA 2.44 ± 0.98 8.19 ± 1.69a 4.67 ± 1.01i,c 4.41 ± 1.00h,g
Reduced glutathione (μmol/l) 829.42 ± 35.00 682.44 ± 76.61a 732.11 ± 38.72a,j 757.88 ± 16.03h,k
Total glutathione (μmol/l) 848.57 ± 34.23 736.11 ± 74.70a 753.66 ± 42.06a 778.66 ± 17.08h
MDA (μmol/l) 1.98 ± 0.47 3.21 ± 0.47a 2.66 ± 0.88f 2.52 ± 0.21j
NO (μmol/ml) 56.82 ± 10.39 84.67 ± 15.93a 71.01 ± 14.12f,j 71.71 ± 6.64f,j
Table 3. Correlation HOMA and some of biochemical parameters
rp
ADMA 0.55 0.001
Reduced glutathione –0.6 0.0001
Total glutathione –0.46 0.006




The present study had shown that fructose rich diet in rats
leads to dyslipidemia condition. The increase in TC, LDL-C, and
triglycerides as well as decrease in HDL-C concentrations may be
as a result of reduced lipoprotein lipase activity secondary to
reduced in plasma insulin levels.(40) Cholesterol ester transfer
protein, which is important in regulating lipoprotein lipid compo-
sition, was increased in DM condition, which may have contributed
to the dyslipidemia.(40) ALA and coenzyme Q10 supplementation
corrected the dyslipidemia occurred. The mechanism action of
ALA is believed through the controlling the activity of enzyme
that involved in lipid metabolism. ALA was found to increase 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
activity and increase lipoprotein lipase and lecithin cholesterol
acyl transferase (LCAT).(41)
Glucose autoxidation and glycation of protein leads to genera-
tion of oxygen free radicals, which can enhance lipid peroxidation
and oxidation of LDL.(42) Fructose fed rats showed significant
Fig. 1. Aorta in a rat from group 1 (HE ×200).
Fig. 2. Perivascular inflammation in group 2 (HE ×400).
Fig. 3. Smooth muscle hypertrophy in group 2 (HE ×400).
Fig. 4. Edema in a vessel in group 2 (HE ×200).
Fig. 5. Edema and infiltration is reduced in group 3 (HE ×100).
Fig. 6. Edema and infiltration is also reduced in group 4 (HE ×100). J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 149
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increase in serum total cholesterol, triglycerides, VLDL, LDL and
decrease in HDL levels. Treatment with CoQ10 significantly
decreased serum cholesterol, triglycerides, VLDL, LDL and
increased HDL levels in diabetic treated rats. Singh et al.(43)
reported that HDL-C concentrations significantly increased in the
group treated by 120 mg/day of CoQ10 than in the control group.
The reduction in lipid levels and increase in HDL levels may be
due to inhibition of LDL oxidation and reduce oxidative stress.
We found that a long-term fructose-rich diet was associated
with an increase in oxidative stress. The increased production of
MDA, nitric oksit, total glutatione and reduced glutathione in
plasma was detected. In the present experiments, CoQ10 and
ALA were used to test the effects of antioxidants on high-fructose
diets CoQ10 and ALA were associated with statistically significant
positive effects. Previous work carried out on ‘ALA supplementa-
tion using the same dose in diabetic rats’ demonstrated beneficial
effects via changes in the oxidative state.(44) Previous reports
confirmed that ALA scavenges hydroxyl radicals, hydrogen
peroxide (H2O2), singlet oxygen, superoxide radicals, and peroxyl
radicals thereby preventing the free radicals-mediated lipid
peroxidation.(45) GSH is the intracellular non-protein sulfhydryl
compound that act as both nucleophile and an effective reductant
by interacting with various electrophilic and oxidized compounds,
and its depletion results in increased defenselessness of cell to
oxidative stress.(46,47) The consequence of decrease in cellular
GSH levels is an increase of free radical intermediates leading to
oxidative stress and potent cellular damage. The reduced form of
GSH becomes readily oxidized to oxidized glutathione (GSSG)
with the Glutatyon peroksidaz (GSH-Px) on interacting with free
radicals.(48,49) In our present study, pretreatment of the rats with
ALA significantly increased the concentration of GSH. It has been
known that the ALA plays an important role in improving the
GSH status through the mechanism of increasing the cystine
availability because cystine is the rate-limiting factor in GSH
biosynthesis. ALA induces the cystine uptake and thereby
increases GSH synthesis. In our present investigation, pretreat-
ment with ALA augments the serum GSH level which is in
accordance with the previous studies.(50)
Impaired endothelium-dependent relaxation has been demon-
strated in various vascular beds in different animal models of
diabetes. The potent antioxidant capacity of ALA, which reduces
oxidative stress both at systemic and local levels, was responsible
for its beneficial action on atherosclerosis and vascular relaxation.
In a recent study,(51) ALA was directly linked to ability to reduce
significantly the elevated total nitrate/nitrite levels of combination-
treated rats. The ability of ALA to modify nitric oxide production
was previously documented, where ALA inhibits lipopolysaccha-
ride-induced NO production in isolated rat Kupffer’s cells and
in murine macrophages.(52) Furthermore, pre-treatment with ALA
prevents NO over production.(53) It has been reported that ALA is
able to decrease the synthesis of NO by preventing the upregula-
tion of iNOS.(52) Another explanation for the reduction of NO
level might be due to the direct scavenging effect of NO by the
sulphydryl group of ALA.(54) Moreover, it has been shown that
ALA is a very potent protector against peroxynitrite-mediated
nitration of L-tyrosine, direct oxidation of glutathione and cellular
damage.(55)
CoQ10 has been considered for improving glycemic control
through various mechanisms, including a decrease in oxidative
stress.(56,57) A study of subjects with type 2 diabetes showed that
CoQ10 therapy lowered blood pressure, improved glycemic
control with a modest decrement in glycated hemoglobin levels.(58)
In fructose rich diet due to oxidative stress there is generation of free
radical which promotes lipid peroxidation. CoQ10 supplementa-
tion was associated with significant reduction in thiobarbituric
acid reactive substances, malondealdehyde and diene conjugates
in coronary artery disease patients.(59) In present study CoQ10
significantly decreased the lipid peroxidation which may be due to
decreased oxidative stress.
Miyazaki et al.(60) were the first to point to a possible association
between ADMA and metabolic pathways. In their cross-sectional
study, they found that patients with the worst insulin tolerance
had the highest plasma concentrations of ADMA. Lin et al.(61)
proposed possible mechanisms by which high glucose levels, a
consequence of insulin resistance, lead to elevated ADMA levels.
The initiation of streptozotocin-induced diabetes in rats reduced
the activity of dimethylarginine dimethylaminohydrolase (DDAH),
which was associated with elevated plasma ADMA levels.
Increasing evidence has demonstrated that ADMA, an endo-
genous NOS inhibitor, is involved in a large number of disorders
characterized by endothelial dysfunction.(62–65) It is also becoming
apparent that DDAH, the metabolizing enzyme for ADMA, has a
potential to regulate NO synthesis through the modulation of
ADMA level.(61,66,67) In our study, ALA decreased serum NO
levels. However, the molecular mechanism of ALA’s effect on NO
production and endothelial function is not fully understood. In this
study, we demonstrated that ALA decreases ADMA level. A
recent study reported that 12-week treatment of ALA in End stage
renal disease (ESRD) patients significantly decreased plasma
ADMA levels.(68) Similar to this clinical observation, we demon-
strate here that ALA treatment decreased ADMA level. In our
study we also observed that CoQ10 administration decreased
ADMA level but this is the first report on effect of CoQ10 admin-
istration in ADMA levels.
The morphological findings of this study have shown that
ultrastructural organization of aorta is disturbed in fructose-
induced metabolic syndrome rats. In the current study, various
morphological changes in endothelial cells indicate of endothelial
injury. Infiltration of lymphocytes in the subendothelial space
and edema of smooth muscle cells were observed in fructose rich
diet rats. These finding were considered to be early events in the
development of the atherosclerotic lesion.(33) In ALA-administered
group, perivascular lymphocytic infiltration was significantly
decreased and even disappeared completely as shown in Fig. 5.
In CoQ10-administered group edema was relatively mild as
shown in Fig. 6; appearances of vessels were almost same with
control group.
In conclusion, our findings suggest that the elevation in insulin
resistance, plasma levels of ADMA and oxidative stress induced
by a fructose diet can be improve by administration of CoQ10 and
ALA. The beneficial effects of CoQ10 or ALA can be attributed
to its antioxidant activity. The protective effects of CoQ10 and
ALA via alterations in the biochemical pathway will be further
investigated.
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